COMMUNIQUÉS West-GlobeNewswire

Microbot Medical® Confirms Continued Operational and Commercial Stability Amid Current Geopolitical Event
03/03/2026
HINGHAM, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY ® Endovascular Robotic System, announced today that the Company, both in the [...]
Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference
03/03/2026
SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its [...]
NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026
03/03/2026
VIS-101, purpose-designed to be a best-in-class dual VEGF-A/ANG-2 inhibitor, has the potential to provide more effective and durable treatment than the current standard of care for patients with wet AMD, DME and RVO [...]
Human Appeal hosts global Grand Iftars, providing over 250,000 meals for vulnerable people this Ramadan
03/03/2026
Humanitarian charity running large scale Iftars for displaced peoples across Palestine, Iraq, Pakistan, Somalia, Sudan, Syria and Yemen MANCHESTER, United Kingdom, March 03, 2026 (GLOBE NEWSWIRE) -- Leading global [...]
Tekton Research Appoints Dr. Jara McDonald as Executive Medical Director to Support Continued Growth in Cardiometabolic Research
03/03/2026
Double Board-Certified Obesity, Diabetes & Integrative Medicine Specialist to Lead Medical Strategy, Sponsor Engagement, and Industry Collaboration AUSTIN, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Tekton Research, [...]
Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial
03/03/2026
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet [...]
Inteleos 2026 Leadership Elections Accelerate Vision for Global Healthcare
03/03/2026
New leadership across the Board and Councils align with the organization’s fifty-year legacy and strategic policy ROCKVILLE, Md., March 03, 2026 (GLOBE NEWSWIRE) -- Inteleos today announced its 2026 leadership elections [...]
Persevere Therapeutics Launches as a Clinical-Stage Oncology Company with a Novel Phase 1b/2a Agent and Announces First Close of Seed Financing
03/03/2026
Chesterbrook, PA, March 03, 2026 (GLOBE NEWSWIRE) -- Persevere Therapeutics, Inc. (“Persevere”), a Delaware-incorporated, clinical-stage oncology biotechnology company, today announced its official launch following a [...]
Spryte Medical Announces First Participants Enrolled in the INSYTE Trial at Baptist Health Jacksonville
03/03/2026
FDA-approved IDE trial to evaluate the safety and effectiveness of the nOCT™ Imaging System to provide quality images for diagnostic assessment during endovascular intracranial aneurysm treatment and follow-up BEDFORD, [...]
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026
03/03/2026
Presentations include three-year follow-up data from patients receiving a one-time 50 milligram (mg) dose of lonvo-z and survey findings highlighting patients’ continued treatment burden and unmet needs CAMBRIDGE, Mass [...]
Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma
03/03/2026
Next-generation, non-invasive diagnostic platform has potential applications in solid tumor types beyond liver cancer Licensing deal reflects Hepion’s strategic shift to advancing clinically proven liquid biopsy tests [...]
Prenetics Executives Execute Second Consecutive Round of Post-Earnings Open Market Share Purchases of $1.3 Million— Cumulative Personal Investment Across Both Rounds Reaches $2.7 Million
03/03/2026
- CEO Danny Yeung makes personal investment in this round of approximately $750,000, up from investment of approximately $502,000 in November 2025 NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited ( [...]
Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026
03/03/2026
NEWTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs [...]
Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share
03/03/2026
Strategic Realignment to Clinical Growth Supported by FDA 510(k) Clearance for Next-Generation Blood Volume Analyzer Oak Ridge, TN, March 03, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader [...]
COUR Pharma Announces Positive One-Year Results from the Phase 2a Study of CNP-104 in Primary Biliary Cholangitis
03/03/2026
CNP-104 improved key cholestasis endpoints at one year, including a composite serum alkaline phosphatase (ALP) and bilirubin biochemical response Durable effects observed across liver stiffness, prognostic risk markers [...]
BioCardia Late Breaking Echocardiography Clinical Results from CardiAMP HF Trial Presented at Technology and Heart Failure Therapeutics (THT)
03/03/2026
Echocardiography outcomes show treated patients having reduced negative remodeling of heart volumes SUNNYVALE, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell- [...]
Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference
03/03/2026
CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced [...]
Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission
03/03/2026
Three-site reproducibility study completed by Tampa General Hospital, Mayo Clinic, and Baylor Scott & White Health Sufficient clinical samples collected to support statistical analysis and FDA submission Company [...]
Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference
03/03/2026
MALVERN, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]

Pages